SOUTH SAN FRANCISCO, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced the pricing of an upsized underwritten public offering of 7,900,677 shares of its common stock at a price to the public of $22.15 per share. Gross proceeds from the underwritten public offering before deducting underwriting discounts and commissions and estimated offering expenses are expected to be approximately $175.0 million. All of the sh ...

Author's note: I present an update my best small and mid-cap stock ideas that insiders are buying only to subscribers of my exclusive marketplace, The Insiders Forum . Our model portfolio has more than doubled the return of its benchmark, the Russell 2000, since its launch. To join our community and gain access to our market beating returns, just click HERE .Shares of floating rate first mortgage loan REIT Seven Hills Realty Trust ( SEVN ) are down nearly 30% in 2025, as Fed easing has squeezed its net inte ...

Thank you for reading my research on Seeking Alpha. If you want to learn even more about my method and how I discover these investment opportunities, please check out my subscription marketplace service, Compounding Healthcare , and sign up for a free trial.My last Collegium Pharmaceutical ( COLL ) article was back in late 2022, where I discussed how the company was gaining momentum and had plenty of upside following their BDSI acquisition. At that time, Xtampza ER wasBiologics is a full-time healthcare inv ...

EnglishItalianoEspañolPortuguêsDeutschالعربيةFrançaisImportant DisclaimersFXEmpire is owned and operated by Empire Media Network LTD., Company Registration Number 514641786, registered at 7 Jabotinsky Road, Ramat Gan 5252007, Israel. The content provided on this website includes general news and publications, our personal analysis and opinions, and materials provided by third parties. This content is intended for educational and research purposes only. It does not constitute, and should not be interpreted a ...

Core Insights - The article emphasizes the importance of identifying underpriced equities with strong upside potential and overappreciated companies with inflated valuations in investment strategies [1] - It highlights the significance of analyzing Free Cash Flow and Return on Capital for deeper investment insights beyond basic profit and sales analysis [1] - The author acknowledges that while underappreciated equities are favored, some growth stocks may justifiably hold premium valuations, necessitating thorough market analysis [1] Industry Focus - The energy sector, particularly oil and gas supermajors, mid-cap, and small-cap exploration and production companies, is a primary focus area for investment analysis [1] - The article also covers a variety of other industries, including mining, chemicals, and luxury goods, indicating a broad analytical approach [1]

Core Insights - The article emphasizes the importance of a hybrid investment strategy that combines classic dividend growth stocks with Business Development Companies, REITs, and Closed End Funds to enhance investment income while achieving total returns comparable to traditional index funds. Group 1: Investment Strategy - The company advocates for a diversified investment approach that includes high-quality dividend stocks and other assets for long-term growth potential [1] - A hybrid system is proposed, blending growth and income strategies to optimize investment returns [1] - The total return achieved through this strategy is reported to be on par with the S&P index [1]

Core Viewpoint - BioAge Labs, Inc. has announced the pricing of its upsized underwritten public offering of 5,897,435 shares at $19.50 per share, aiming to raise approximately $115.0 million before expenses [1]. Group 1: Offering Details - The offering is expected to close on or about January 23, 2026, subject to customary closing conditions [1]. - BioAge has granted underwriters a 30-day option to purchase an additional 884,615 shares [1]. - Goldman Sachs & Co. LLC, Piper Sandler, and Citigroup are acting as joint book-running managers for the offering [2]. Group 2: Use of Proceeds - The net proceeds will be used to fund research, clinical and process development, and manufacturing of product candidates, including BGE-102, as well as working capital, capital expenditures, and reduction of indebtedness [3]. Group 3: Company Overview - BioAge is a clinical-stage biopharmaceutical company focused on developing therapeutic candidates for metabolic diseases by targeting human aging biology [6]. - The lead product candidate, BGE-102, is a small-molecule NLRP3 inhibitor for cardiovascular risk and retinal diseases, with a Phase 1 trial currently underway [6].

Core Insights - Elastic N.V. (ESTC) is identified as undervalued, with a potential upside of approximately 30% from its stock price of around $74.5 to the estimated Fair Value [1] Group 1: Investment Strategy - The investment style is described as "Fundamental Options," combining fundamental analysis with options strategies [1] - Various investment strategies are pursued, including income-oriented investments, growth at a reasonable price, deep value based on discounted cash flow, and dividend aristocrats [1] - The analyst employs 20-25 options strategies for purposes such as hedging, bullish substitutes, neutral trades, trading volatility, and earnings-related trades [1] Group 2: Background and Teaching - The analyst has a background in software development, which informs their focus on technology investments [1] - Teaching is a passion, with experience in both formal and informal education, including authoring a free local investing newsletter [1]

Group 1 - Brazilian equities are entering 2026 with a more nuanced but still constructive outlook after a strong rally in 2025 driven by flows [1] - The investment thesis for the iShares MSCI Brazil ETF (EWZ) has shifted away from distressed valuations [1] Group 2 - The analysis focuses primarily on Brazilian and Latin American stocks, with occasional insights into global large caps [1]

Core Viewpoint - The finance sector is experiencing a solid start to the Q4 earnings season, with many companies exceeding consensus estimates and providing a stable-to-positive outlook for their businesses [5][7]. Finance Sector Performance - Major banks like JPMorgan, Bank of America, and Citigroup have shown disappointing market reactions despite not having negative Q4 results, indicating a 'sell-the-news' phenomenon after their recent outperformance [2]. - Citigroup shares have outperformed peers and the broader market over the past year, driven by investor confidence in the new management's restructuring plans [3]. - However, shares of Citigroup, Bank of America, and JPMorgan have been declining since the start of the year, with Q4 earnings results contributing to this downtrend [4]. Earnings Growth and Estimates - Total earnings for the 51 S&P 500 companies that reported Q4 results are up 17.2% year-over-year, with revenues increasing by 7.5%. Notably, 88.2% of these companies beat EPS estimates and 72.5% exceeded revenue estimates [5]. - For the finance sector, earnings are up 13.9% year-over-year with revenues rising by 7.0%. Additionally, 90.5% of finance companies beat EPS estimates and 71.4% surpassed revenue estimates [5]. Macroeconomic Outlook - Management teams are optimistic about consumer spending and stable credit quality trends, with a positive outlook for loan demand and investment banking advisory services, despite some policy uncertainties [7]. - The overall outlook remains positive, although there are headwinds related to the administration's credit card plans [7]. Sector Contributions - The tech sector is projected to contribute 36% of the S&P 500's total earnings over the next four quarters and currently represents 42.5% of the index's total market capitalization, highlighting its significant role in the overall earnings picture [16].